Literature DB >> 33753286

A study design for statistical learning technique to predict radiological progression with an application of idiopathic pulmonary fibrosis using chest CT images.

Grace Hyun J Kim1, Yu Shi2, Wenxi Yu2, Weng Kee Wong3.   

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease characterized by an unpredictable decline in lung function. Predicting IPF progression from the early changes in lung function tests have known to be a challenge due to acute exacerbation. Although it is unpredictable, the neighboring regions of fibrotic reticulation increase during IPF's progression. With this clinical information, quantitative characteristics of high-resolution computed tomography (HRCT) and a statistical learning paradigm, the aim is to build a model to predict IPF progression.
DESIGN: A paired set of anonymized 193 HRCT images from IPF subjects with 6-12 month intervals were collected retrospectively. The study was conducted in two parts: (1) Part A collects the ground truth in small regions of interest (ROIs) with labels of "expected to progress" or "expected to be stable" at baseline HRCT and develop a statistical learning model to classify voxels in the ROIs. (2) Part B uses the voxel-level classifier from Part A to produce whole-lung level scores of a single-scan total probability's (STP) baseline.
METHODS: Using annotated ROIs from 71 subjects' HRCT scans in Part A, we applied Quantum Particle Swarm Optimization-Random Forest (QPSO-RF) to build the classifier. Then, 122 subjects' HRCT scans were used to test the prediction. Using Spearman rank correlations and survival analyses, we ascertained STP associations with 6-12 month changes in quantitative lung fibrosis and forced vital capacity.
CONCLUSION: This study can serve as a reference for collecting ground truth, and developing statistical learning techniques to predict progression in medical imaging.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Machine learning; Medical image; Particle swap optimization; Quantitative lung fibrosis; Random forest

Mesh:

Year:  2021        PMID: 33753286      PMCID: PMC8204677          DOI: 10.1016/j.cct.2021.106333

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  34 in total

1.  Comparison of the quantitative CT imaging biomarkers of idiopathic pulmonary fibrosis at baseline and early change with an interval of 7 months.

Authors:  Hyun J Kim; Matthew S Brown; Daniel Chong; David W Gjertson; Peiyun Lu; Hak J Kim; Heidi Coy; Jonathan G Goldin
Journal:  Acad Radiol       Date:  2014-09-26       Impact factor: 3.173

2.  Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide.

Authors:  Hyun J Kim; Matthew S Brown; Robert Elashoff; Gang Li; David W Gjertson; David A Lynch; Diane C Strollo; Eric Kleerup; Daniel Chong; Sumit K Shah; Shama Ahmad; Fereidoun Abtin; Donald P Tashkin; Jonathan G Goldin
Journal:  Eur Radiol       Date:  2011-09-17       Impact factor: 5.315

3.  Sample-size formula for the proportional-hazards regression model.

Authors:  D A Schoenfeld
Journal:  Biometrics       Date:  1983-06       Impact factor: 2.571

4.  Machine Learning in Medical Imaging.

Authors:  Miles N Wernick; Yongyi Yang; Jovan G Brankov; Grigori Yourganov; Stephen C Strother
Journal:  IEEE Signal Process Mag       Date:  2010-07       Impact factor: 12.551

5.  Radiological versus histological diagnosis in UIP and NSIP: survival implications.

Authors:  K R Flaherty; E L Thwaite; E A Kazerooni; B H Gross; G B Toews; T V Colby; W D Travis; J A Mumford; S Murray; A Flint; J P Lynch; F J Martinez
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

6.  Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Authors:  Luca Richeldi; Roland M du Bois; Ganesh Raghu; Arata Azuma; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Kevin R Flaherty; David M Hansell; Yoshikazu Inoue; Dong Soon Kim; Martin Kolb; Andrew G Nicholson; Paul W Noble; Moisés Selman; Hiroyuki Taniguchi; Michèle Brun; Florence Le Maulf; Mannaïg Girard; Susanne Stowasser; Rozsa Schlenker-Herceg; Bernd Disse; Harold R Collard
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

7.  Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis.

Authors:  Scott M Palmer; Laurie Snyder; Jamie L Todd; Benjamin Soule; Rose Christian; Kevin Anstrom; Yi Luo; Robert Gagnon; Glenn Rosen
Journal:  Chest       Date:  2018-09-07       Impact factor: 9.410

8.  Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).

Authors:  Suzanne Kafaja; Philip J Clements; Holly Wilhalme; Chi-Hong Tseng; Daniel E Furst; Grace Hyun Kim; Jonathan Goldin; Elizabeth R Volkmann; Michael D Roth; Donald P Tashkin; Dinesh Khanna
Journal:  Am J Respir Crit Care Med       Date:  2017-11-03       Impact factor: 30.528

9.  Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.

Authors:  Steven D Nathan; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Roland M du Bois; Elizabeth A Fagan; Robert S Fishman; Ian Glaspole; Marilyn K Glassberg; Kenneth F Glasscock; Talmadge E King; Lisa Lancaster; David J Lederer; Zhengning Lin; Carlos A Pereira; Jeffrey J Swigris; Dominique Valeyre; Paul W Noble; Athol U Wells
Journal:  Thorax       Date:  2016-03-11       Impact factor: 9.139

10.  Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Authors:  Ganesh Raghu; Martine Remy-Jardin; Jeffrey L Myers; Luca Richeldi; Christopher J Ryerson; David J Lederer; Juergen Behr; Vincent Cottin; Sonye K Danoff; Ferran Morell; Kevin R Flaherty; Athol Wells; Fernando J Martinez; Arata Azuma; Thomas J Bice; Demosthenes Bouros; Kevin K Brown; Harold R Collard; Abhijit Duggal; Liam Galvin; Yoshikazu Inoue; R Gisli Jenkins; Takeshi Johkoh; Ella A Kazerooni; Masanori Kitaichi; Shandra L Knight; George Mansour; Andrew G Nicholson; Sudhakar N J Pipavath; Ivette Buendía-Roldán; Moisés Selman; William D Travis; Simon Walsh; Kevin C Wilson
Journal:  Am J Respir Crit Care Med       Date:  2018-09-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.